CTLA4 and non-small cell lung carcinoma: In NSCLC patients treated with anti‐CTLA‐4, common irAEs include skin rashes (13.3%–41%), liver inflammation (5%–42%) and digestive problems such as diarrhoea (27%–30%), nausea (8%–18%) and colitis (8.8%–19%) (Table 1),7, 11, 27, 28, 29, 30 as depicted in Table 1.